The capacity to identify metastatic disease based on proto-oncogenes such as Kirsten rat sarcoma viral oncogene homolog (KRAS) and tumor suppressor p53 (TP53), present in only half of the lung cancer patients (47 and 50%, respectively) (25), demands a more broaden and deepened spectrum of the investigation of primary lung cancers, the molecular interactions with other cells, and the tumor microenvironment. The gene discussed is TP53; the disease is lung carcinoma.